Cipla’s wholly-owned subsidiary -- Cipla USA Inc. has acquired the prescription drug ZEMDRI (Plazomicin) from Achaogen Inc. in a Chapter 11, US Bankruptcy Code auction of Achaogen’s assets. Cipla USA has acquired worldwide rights of ZEMDRI (excluding Greater China) with its allied assets and limited liabilities.
ZEMDRI is a once-daily novel intravenous (IV) aminoglycoside for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis, in adults who are unresponsive to currently available treatment options.
Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. The company’s portfolio includes over 1500 products across wide range of therapeutic categories with one quality standard globally.
